IXICO PLC (AIM:IXI, OTC:PHYOF) told investors it has been selected by a leading global pharmaceutical company, and new client, to provide MRI imaging services for an early phase clinical trial in Multiple System Atrophy.
The company, in a statement, said it had signed a start-up agreement with the client and it is anticipated to extend to a contract value of approximately £0.6mln early in 2023.
Yesterday, the company separately reported that it had been notified by a client that the client has decided to discontinue a phase two trial. It noted that it is expected to result in a reduction in management's previously anticipated revenues for 2023 of £0.1mln and a total reduction in the company's orderbook of £0.6mln, though market guidance will not be impacted.